Terns Pharmaceuticals, Inc.(TERN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
TERN Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Terns Pharmaceuticals, Inc. (TERN), a Healthcare sector company. TERN is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Top institutional holders of TERN by reported 13-F value include BlackRock,, MORGAN STANLEY, Avoro Capital Advisors, based on the most recent SEC filings. TERN trades on the Nasdaq exchange and files with the SEC under CIK 1831363. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TERN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Terns Pharmaceuticals, Inc. directly from SEC EDGAR.
Free Cash Flow
Q4 2025
$-19.1M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
-6.6% YoYOperating Income
-7.4% YoYEPS (Diluted)
+18.9% YoYTotal Assets
+281.8% YoYTotal Debt
Op. Cash Flow
-21.9% YoY| Metric | FY 2025 | FY 2023 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Revenue | — | — | $1.0M | $0.00 |
| Net Income | $-96.2M -6.6% | $-90.2M -79.9% | $-50.2M -25.2% | $-40.1M |
| Operating Income | $-110.1M -7.4% | $-102.6M -105.7% | $-49.9M -34.7% | $-37.0M |
| EPS (Diluted) | $-1.03 +18.9% | $-1.27 +42.5% | $-2.21 | — |
| Total Assets | $1.03B +281.8% | $268.5M +59.8% | $168.1M +82.1% | $92.3M |
| Total Debt | — | $0.00 | — | — |
| Operating Cash Flow | $-82.2M -21.9% | $-67.4M -61.1% | $-41.8M -40.3% | $-29.8M |
Get alerted when TERN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Terns Pharmaceuticals, Inc. including:
Top Institutional Holders of TERN
BlackRock, Inc.
$504.5M9,569,585 shMORGAN STANLEY
$340.0M6,449,140 shAvoro Capital Advisors LLC
$300.2M5,695,000 shVANGUARD CAPITAL MANAGEMENT LLC
$229.6M4,355,482 shHolocene Advisors, LP
$217.0M4,115,828 shCITADEL ADVISORS LLC
$169.7M3,218,810 shMILLENNIUM MANAGEMENT LLC
$158.8M3,011,558 shHBK INVESTMENTS L P
$155.5M2,950,000 shBALYASNY ASSET MANAGEMENT L.P.
$146.5M2,779,445 shFRANKLIN RESOURCES INC
$127.0M2,409,019 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $504.5M | 9,569,585 |
| MORGAN STANLEY | $340.0M | 6,449,140 |
| Avoro Capital Advisors LLC | $300.2M | 5,695,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $229.6M | 4,355,482 |
| Holocene Advisors, LP | $217.0M | 4,115,828 |
| CITADEL ADVISORS LLC | $169.7M | 3,218,810 |
| MILLENNIUM MANAGEMENT LLC | $158.8M | 3,011,558 |
| HBK INVESTMENTS L P | $155.5M | 2,950,000 |
| BALYASNY ASSET MANAGEMENT L.P. | $146.5M | 2,779,445 |
| FRANKLIN RESOURCES INC | $127.0M | 2,409,019 |
More Healthcare Companies
View all Healthcare →Put TERN on your watchlist
Track score changes the day Terns Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TERN a good stock to buy?
13F Pro's AI-powered analysis of Terns Pharmaceuticals, Inc. (TERN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TERN are available on the TERN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own TERN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TERN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Terns Pharmaceuticals, Inc.'s investment landscape.